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Background
Since the introduction of combined anti-retroviral ther-
apy (cART), survival of patients with HIV-associated NHL
improved dramatically. We examined survival and HIV-
related prognostic factors of patients with HIV-related
NHL in the era of cART within the framework of a large
European multi-cohort collaborative study.
Methods
We analyzed the data of HIV-infected adult patients (age
> 16 years) who developed a NHL after January 1, 1998.
We included patients who were cART naïve at inclusion
and started cART after January 1, 1998. Only patients who
started cART at some point during lifetime were included
in the present analysis. cART was defined as regimen with
at least three antiretroviral drugs. Patients had to have at
least one CD4 cell count measurement after January 1,
1998, and before or within 7 days of NHL diagnosis. Sur-
vival and prognostic factors were estimated using crude
and adjusted Weibull models, with random-effects
accounting for heterogeneity between cohorts.
Results
We observed 67,659 HIV-infected patients. Of 1,176
patients who developed NHL, 847 (72%) NHL patients
from 22 collaborating cohorts across Europe were
included in the present analysis. The 329 (28%) NHL
patients who did not meet the inclusion criteria outlined
above were excluded. After 1 year, 66 percent (95% CI
63%–70%) of patients with NHL other than Primary
Brain Lymphoma (PBL) and 54 percent (95% CI 43%–
65%) of patients with PBL were alive. Negative predictive
factors for survival were diagnosis of PBL, low CD4 cell
count nadir and history of injection drug use.
Conclusion
In the era of cART two-thirds of patients diagnosed with
HIV-related NHL other than PBL survive for longer than 1
year after diagnosis. Survival is poorer in patients diag-
nosed with PBL.
More advanced immunodeficiency is the dominant prog-
nostic factor for mortality in patients with HIV-related
NHL.
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